Compare ALLT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 462.2M |
| IPO Year | 2006 | 2019 |
| Metric | ALLT | FULC |
|---|---|---|
| Price | $7.07 | $8.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $12.40 | ★ $16.38 |
| AVG Volume (30 Days) | 344.2K | ★ 1.0M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.08 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $2.32 |
| 52 Week High | $11.92 | $15.74 |
| Indicator | ALLT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 52.75 |
| Support Level | $6.20 | $6.33 |
| Resistance Level | $8.20 | $8.17 |
| Average True Range (ATR) | 0.29 | 0.49 |
| MACD | 0.17 | 0.19 |
| Stochastic Oscillator | 100.00 | 95.73 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.